Boiardi A, Silvani A, Milanesi I, Botturi M, Broggi G
Istituto Nazionale Neurologico C. Besta, Milano.
Ital J Neurol Sci. 1992 Dec;13(9):717-22. doi: 10.1007/BF02229155.
The aim of this study was to verify the tolerability and efficacy of therapeutic chemotherapy protocols, employing different combinations of cisplatin, carboplatin, etoposide and carmustine in primary glioblastoma patients. The purpose was focused on 2 end points: the response index to treatment, the TTP (tumor progression) and the ST (survival time). Eighty-four out of a group of 99 consecutive glioblastoma patients, entered this study. Patients were divided into 4 disparate treatment groups: (A) BCNU alone; (B) CDDP + VP-16; (C) CBDCA + BCNU; (D) CBDCA + BCNU + VP-16. The effectiveness and the TTP of the protocols differed, but differences were not statistically significant. Data concerning platinum treatment compare favorably with the best literature results. At 18 months more than half the carboplatin-treated patients are alive. Moreover these patients had a significantly longer ST than those treated with BCNU. We conclude that platinum-based chemotherapy has a beneficial effect on glial tumors.
本研究的目的是验证治疗性化疗方案的耐受性和疗效，该方案采用顺铂、卡铂、依托泊苷和卡莫司汀的不同组合用于原发性胶质母细胞瘤患者。目的集中在两个终点：治疗反应指数、无进展生存期（TTP）和生存时间（ST）。在连续的99例胶质母细胞瘤患者中，有84例进入了本研究。患者被分为4个不同的治疗组：（A）单独使用卡莫司汀；（B）顺铂+依托泊苷；（C）卡铂+卡莫司汀；（D）卡铂+卡莫司汀+依托泊苷。各方案的有效性和无进展生存期有所不同，但差异无统计学意义。关于铂类治疗的数据与最佳文献结果相比具有优势。在18个月时，超过一半接受卡铂治疗的患者仍然存活。此外，这些患者的生存时间明显长于接受卡莫司汀治疗的患者。我们得出结论，铂类化疗对神经胶质瘤有有益作用。
